clinical trial · NCT07088159
Intermediate-size Patient Population Expanded Access Protocol
Spinogenix·—·available
ALS (Amyotrophic Lateral Sclerosis)Tazbentetol
brief summary
The purpose of this Expanded Access Program is to provide tazbentetol to ALS patients who are not eligible to enroll in an ALS clinical trial. This Expanded Access Program will assess safety and tolerability, and clinical efficacy of tazbentelol.
started
—
primary completion
—
completion
—
last updated
Jul 17, 2026
detailed description
This is a multi-site, intermediate-size patient population expanded access protocol developed to provide compassionate use access to tazbentetol to adult patients with ALS who have progressed following available standard of care.
official title
Intermediate-size Patient Population Expanded Access Protocol for Tazbentetol in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol